This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

Gene therapy represents one of the fastest growing biotherapeutics worldwide, with AAV at the forefront. This rapid growth is constantly challenging CMC approaches, from manufacturing through release ...

Isolere Bio by Donaldson, an innovative bioprocessing technology provider, proudly announces the availability of its manufacturing-grade IsoTag™ AAV reagent for the purification of Adeno ...

To assist researchers in the selection of the optimal AAV vector for their application, we have generated a detailed map of viral delivery to tissues in mice, the most commonly used experimental ...

Adeno-associated viral (AAV) vectors are viruses used to deliver gene therapies to different cells. They are considered one of the field’s most effective delivery tools. AAVs show particular ...

Adeno-associated virus (AAV) gene therapies hold great promise, but ensuring product quality is critical. One major challenge? The presence of empty capsids, which can reduce therapeutic effectiveness ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...